Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAF-HCM aficamten in asymptomatic obstructive hypertrophic cardiomyopathy
NL-OMON61618Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Primary endpoint: Change in post-Valsalva left ventricular outflow tract gradient. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON61618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61618.